Treatment for rare lung infection kills one in four patients with diabetic ketoacidosis

Diabetic ketoacidosis is a dangerous complication of diabetes where the body produces too much acid. When this condition leads to a rare lung infection called pulmonary mucormycosis, the outlook is often grim. A recent look at 16 patients shows that one in four people with this specific combination died. This group included one detailed case report and 15 cases gathered from medical literature. The infection was caused by a fungus known as Rhizopus. Doctors treated these patients with amphotericin B-based therapy and performed surgery to remove localized lesions when possible. They also worked to correct the underlying metabolic issues. The review did not report any specific safety signals or side effects for the drugs used in these cases. However, the data comes from a small number of patients and a mix of treatment settings. This means the results reflect real-world complexity rather than a single controlled experiment. The main lesson is clear: doctors must keep a high index of clinical suspicion in high-risk hosts. Early pathological or molecular diagnosis is vital. Prompt antifungal therapy alongside metabolic correction saves lives. Timely surgical evaluation for localized lesions remains a critical part of care. Maintaining these practices could improve outcomes for patients facing this deadly threat.